An ICC Arbitral Tribunal has issued a major quantum award totaling approximately EUR 112 million to AOP Orphan Pharmaceuticals GmbH (AOP Health). The ruling resolves long-standing damages claims against PharmaEssentia Corp. regarding their licensing contract for BESREMi (ropeginterferon alfa-2b). Specifically, the ICC Arbitral Tribunal determined that PharmaEssentia owes EUR 82 million for intentional contract breaches. Furthermore, the tribunal awarded EUR 31 million plus interest to reimburse AOP Health for product overcharges between 2019 and 2022. Crucially, judges confirmed that PharmaEssentia overcharged AOP Health by up to 900 percent during those years.
In addition, the ICC Arbitral Tribunal affirmed AOP Health’s right to offset EUR 17 million in profit-sharing payments. Consequently, AOP Health owes zero payment to PharmaEssentia going forward. Interest will continue accruing on AOP Health’s awarded claims until PharmaEssentia fulfills its legal financial obligations. Meanwhile, the panel dismissed all remaining counterclaims submitted by PharmaEssentia during this quantum phase.
This definitive decision follows a partial final award delivered in February 2025. At that time, arbitrators established PharmaEssentia’s intentional liability under the original licensing agreement. Applying this same pricing formula to deliveries from 2023 through 2025 reveals another EUR 65 million in excessive charges. Therefore, PharmaEssentia’s total potential liability now reaches well into the three-digit million-euro range.
Ensuring Uninterrupted Patient Access and Market Stability
Despite legal battles, AOP Health continues securing stable access to BESREMi for rare blood cancer patients. Now in its seventh year since European Medicines Agency approval, the therapy reaches roughly 12,600 patients across licensed territories.
Dr. Rudolf Widmann, one of the two founders of AOP Health, says: “After eight years of legal dispute, we welcome the tribunal’s decision because it reduces uncertainty. This award gives us a stronger basis to continue our mission: developing and making available medicines that address high unmet medical needs.”
However, legal proceedings may continue across German appellate courts. PharmaEssentia retains options to seek limited reviews of this quantum decision before competent German judiciary panels. Meanwhile, review proceedings for the initial 2025 liability award remain pending before the German Federal Court of Justice. The Higher Regional Court of Frankfurt had previously confirmed the underlying merit award in April 2026.
Historical Background of the Transborder Licensing Debate
The commercial dispute dates back to 2009, when AOP Health bought the development and distribution rights for BESREMi. The coverage territory covers the European, Commonwealth of Independent States and Middle Eastern healthcare markets. The trouble began in 2017 when PharmaEssentia tried to unilaterally terminate the licensing contract. But an ICC Arbitral Tribunal threw out those termination efforts in October 2020.
PharmaEssentia then filed additional legal proceedings in November 2020. AOP Health has responded with a countersuit for delays in European regulatory approval and misuse of clinical data. The ICC Arbitral Tribunal’s decision confirms AOP Health’s strong legal position throughout the trial.
In the end, this decision highlights the need for international biopharmaceutical licensing compliance enforcement. “AOP Health fought for its commercial rights through persistent litigation and also ensured vital drug supplies. The ICC Arbitral Tribunal’s decision sets clear financial responsibility for intentional price inflation in the supply chain. AOP Health will continue to build its pipeline of clinical development programs in specialized indications in global markets going forward.
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
Source: Businesswire
